Document Detail


Scintigraphic parameters with emphasis on perfusion appraisal in rest 99mTc-sestamibi SPECT in the recovery of myocardial function after thrombolytic therapy in patients with ST elevation myocardial infarction (STEMI).
MedLine Citation:
PMID:  21593086     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: This study was performed to determine the clinical application of rest 99mTc-sestamibi in the assessment of viability and functional improvement of the left ventricle (LV) myocardium in the post-thrombolytic therapy of acute myocardial infarction (AMI).
MATERIAL AND METHODS: In 37 patients with AMI who received thrombolytic therapy, 2-dimensional (2D) echocardiography, as well as the resting redistribution of 99mTc-sestamibi, was investigated, both within 1 week and 3-5 months after AMI. The predictive capacity of the perfusion percentage for myocardial function recovery was evaluated. Also, the capacities of the possible variables in the prediction of recovery of myocardial function resulting from a change in LV ejection fraction (EF) were evaluated using stepwise multiple regression analysis.
RESULTS: Thirty-seven patients (30 men and 7 women; mean age: 58±14 years) with AMI were enrolled in the study. Redistribution was observed in 35 and 50 segments of the initial and follow-up scans, respectively. In addition, 146 segments with reverse redistribution (RR), both in the initial scan (118 segments) and the follow-up scan (86 segments), were also observed. An apparent difference in wall motion scores was seen between the initial and follow-up echocardiographs (p<0.001). Furthermore, using the optimal cut-off point of perfusion percentage in each image set, sensitivity as well as specificity and likelihood ratio (LR) for the improvement of regional wall motion after 3-5 months were defined.
CONCLUSION: These data showed that redistribution and reverse redistribution of 99mTc-sestamibi post thrombolytic therapy can be used as a marker of viability to predict the recovery of segmental wall motion abnormality (stunning), as well as the improvement of segmental perfusion uptake. This study also demonstrates that the resting 99mTc-sestamibi SPECT can be used for an approximate assessment of LV function status and can predict the recovery of jeopardized myocardium function after thrombolytic therapy.
Authors:
H Javadi; M A Porpiranfar; S Semnani; S Jallalat; P Yavari; M Mogharrabi; A Hooman; A Amini; M Barekat; D Iranpour; M Seyedabadi; M Assadi; I N Asli
Related Documents :
15144936 - Commentary on the carvedilol or metoprolol european trial (comet).
21941646 - Role of stress myocardial scintigraphy in the evaluation of incompletely revascularized...
17719466 - Resting heart rate in cardiovascular disease.
21996026 - Circulating levels of hepatocyte growth factor and left ventricular remodelling after a...
720026 - Bedside management of acute myocardial infarction.
10426326 - Significance of dobutamine-induced st-segment evaluation and t-wave pseudonormalization...
Publication Detail:
Type:  Journal Article     Date:  2011-05-18
Journal Detail:
Title:  Perfusion     Volume:  26     ISSN:  1477-111X     ISO Abbreviation:  Perfusion     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-09-08     Completed Date:  2011-12-30     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  8700166     Medline TA:  Perfusion     Country:  England    
Other Details:
Languages:  eng     Pagination:  394-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography / methods*
Echocardiography / methods
Female
Heart Ventricles* / physiopathology,  radiography,  ultrasonography
Humans
Male
Middle Aged
Myocardial Infarction* / physiopathology,  radiography,  therapy,  ultrasonography
Radiopharmaceuticals / administration & dosage*
Recovery of Function
Technetium Tc 99m Sestamibi / administration & dosage*
Thrombolytic Therapy*
Ventricular Function, Left
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 971Z4W1S09/Technetium Tc 99m Sestamibi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Retrograde autologous priming reduces transfusion requirements in coronary artery bypass surgery.
Next Document:  Carboxyhemoglobinemia in a pediatric cardiopulmonary bypass patient derived from a contaminated unit...